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bstract
Influenza causes substantial mortality in high-risk groups despite targeted vaccination programmes. This paper considers whether it is
orth vaccinating healthcare workers (HCWs) against influenza to protect high-risk patients in a series of systematic reviews and an economic
valuation. Eighteen studies are included. Vaccination was highly effective in HCWs, with minimal adverse effects. Two trials assessed patient
ortality after vaccinating HCWs, both of which showed a reduction. Despite recommendations, less than 25% of HCW in Europe and the UK
re vaccinated. Five studies looked at programmes to increase uptake; these produced increases of 5%–45%. Published economic evaluations
id not include patient benefit; therefore, an economic evaluation using UK data was undertaken. In the base case, vaccination was cost saving
£12/vaccinee). In the most pessimistic scenario it cost £405/life-year gained. Effective implementation should be a priority.
2006 Elsevier Ltd. All rights reserved.
eywords: Healthcare workers; Influenza vaccination; Systematic review; Economic evaluation
. Introduction
Appropriate policies for healthcare not only require infor-
ation about effectiveness, safety and cost-effectiveness,
ut also need adequate implementation. Influenza is an
mportant public health problem and it causes significant
ortality particularly in the elderly and high-risk groups
1]. An obvious policy is to vaccinate those most at risk
nd most countries in Europe and North America have such
rogrammes [2]. Although the benefit of vaccination is
∗ Corresponding author. Tel.: +44 121 414 7508; fax: +44 121 414 7878.
E-mail address: a.j.burls@bham.ac.uk (A. Burls).
 Deceased.
well documented [3,4], there remains significant influenza-
associated morbidity and mortality in the high-risk. A
complementary approach to protecting the vulnerable could
be to provide indirect protection by vaccinating others to
reduce transmission of influenza. Vaccination of children
has been shown to have the potential to reduce morbidity
and mortality in others [5]. Healthcare workers (HCWs)
can cause outbreaks in patients in the healthcare setting [6].
Although the World Health Organisation recommends that
HCWs should be vaccinated against influenza [1], policy in
Europe is variable and uptake poor (less than 25%) [2,7].
Research was commissioned by the European Scientific
Working Group on Influenza (ESWI) to look at the effective-
ness and cost-effectiveness of vaccinating HCWs as an indi-
264-410X/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
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rect means of protecting high-risk patients against influenza.
This paper integrates the findings from systematic reviews
looking at the effectiveness, cost-effectiveness and factors
affecting uptake, and an economic evaluation.
2. Methods
2.1. Search strategy
We searched electronic databases (Cochrane library,
CINAHL, NHSEED, HEED, DARE, MEDLINE and
EMBASE to June 2004), Internet sites, registers of trials,
citation lists and contacted experts. No language restrictions
were applied. (Full details available on request.)
Key words used: influenza; health personnel; health care
worker; health worker; care giver; physician; medical staff;
nurses; nursing home; homes for the aged; residential home;
vaccination; influenza vaccine.
2.2. Inclusion criteria
Studies were included if they fulfilled the following crite-
ria:
Design: Any
Comparator: No vaccination, placebo or vaccine unrelated
to influenza
Primary outcomes (in high-risk contacts): Culture or sero-
logically confirmed influenza; all-cause mortality; mortal-
ity attributed to influenza/pneumonia; influenza-like illness;
influenza-related morbidity; cost or cost-effectiveness.
Secondary outcomes (in vaccinated population): Effective-
ness; adverse events; acceptability; uptake; methods of
attaining uptake; absenteeism.
2.3. Selection, quality assessment and data extraction
Studies were selected, appraised (using validated check-
lists [8,9]), and data extracted by two reviewers indepen-
dently. Discrepancies were resolved by discussion. Results
were tabulated and described. Meta-analyses were consid-
ered inappropriate because of heterogeneity in populations,
settings and design.
2.4. Economic evaluation
No economic evaluation was found that included indi-
rect effects on patients. A simple decision analytic model of
the cost-effectiveness of a programme of vaccinating HCWs,
compared to no programme, was constructed in Excel®. It
used the key Carman trial [10] (details below) to provide data
f
c
tPopulation: HCWs in hospitals, nursing homes or the com-
munity in contact with high-risk individuals
Intervention: Influenza vaccinationFig. 1. Flow of study selection for effectiveness, resources and costs concerning the vaccine,
ampaign, staff time, staff ratios and absenteeism. Informa-
ion from the above systematic review, published literatureor clinical effectiveness.
4214 A. Burls et al. / Vaccine 24 (2006) 4212–4221
and routine data informed other parameters. The perspective
is that of the healthcare provider—both direct effects of pre-
venting influenza in those vaccinated and indirect effects of
protecting patients are included. UK costs are for 2003–2004.
Future benefits are discounted at 3.5%. Adverse effects are
assumed to be negligible and have no effect on absenteeism.
Costs of replacing staff use standard rates (agency rates would
be higher giving a more favourable cost-effectiveness ratio for
vaccination).
3. Results
We identified 493 studies relating to vaccinating health-
care workers. Eighteen met the inclusion criteria [10–27] (see
Fig. 1). Details of the studies are given in Table 1.
3.1. Does vaccinating HCWs protect those at risk?
The main evidence comes from two cluster-randomised
controlled trials (RCTs) performed in the 1990s in long-
term care geriatric hospitals in Scotland: Carman et al. [10]
and Potter et al. [11] (Table 2). Both trials were of reason-
able quality, of appropriate cluster design (although small
numbers of clusters) and used methods to allow for base-



























ranged from 34% to 100%. Common reasons for refusing
vaccination were:
• fear of side effects (8%–51%) [18–27];
• fear that vaccination would cause influenza (21%–45%)
[21,25];
• dislike of injections (5%–27%) [18–21,23–27];
• unaware the vaccine was available/useful (3%–53%)
[21,22,25–27];
• forgetting/lack of time (5%–60%) [18,20,22–24,26,27];
• perceived low risk of contracting influenza (5%–29%)
[18,20,21].
Those who were vaccinated did so mainly to protect
themselves (82%–83%), with 62%–67% wishing to protect
patients [19,24].
3.3. What are the effects of inﬂuenza vaccine on the
recipients?
Three randomised controlled trials reported the effects of
influenza vaccine on HCWs [12–14] (Table 3). Two were
of good quality [12,14]. Randomisation methods, blinding
and loss-to-follow up were not adequately reported in the
third [13]. One good study [12] reported a statistically signif-
icant reduction in rates of serologically confirmed or clinical


























e10] the method of cluster analysis was not clearly reported.
oth demonstrated clinically significant reductions in mor-
ality when a staff vaccination programme was introduced.
n the Potter trial [11], a reduction from 17% to 10% was
eported, with a p-value (adjusted for cluster design) of
.013. The odds ratio (OR) was 0.56 (95% CI 0.4, 0.8) but
hese confidence intervals did not appear to take account
f the clustered design and should be interpreted with cau-
ion. In the main trial, Carman, 20 hospitals were stratified,
aired for patient vaccination policy and size, and randomly
ssigned within each pair to a programme of offering vac-
ination to all HCWs, or no programme. In the programme
rm 51% of HCWs were vaccinated, and 5% in the con-
rol arm. The vaccine was a good match to circulating virus.
ncorrected mortality was 13.6% in the vaccinated arm com-
ared to 22.4% in control arm (OR 0.58, 95% CI 0.40–0.84,
= 0.014). The difference remained statistically significant
hen the analysis was adjusted for individual confounders.
hen all confounders, i.e., Barthel score, age, sex and vacci-
ation of patients were adjusted for simultaneously, the result
as of borderline statistical significance (OR = 0.61, 95% CI
.36–1.04).
.2. Why are inﬂuenza vaccine uptake rates low in
CWs?
Ten studies assessed reasons why HCWs receive or decline
nfluenza vaccine using questionnaires [18–27].
Survey methods, setting and staff categories varied widely
nd studies cannot be directly compared. Response ratesor influenza A. The other two trials reported no difference
lthough in one there was a poor vaccine match [14] and in
he other the incidence of influenza was low [13]. A high
uality systematic review [28] found that vaccination would
educe absenteeism by about 0.4 (95% CI 0.1–0.8) working
ays per person vaccinated in healthy adults. Only one study
eported a statistically significant mean reduction in absen-
eeism due to respiratory infection in the intervention group:
.0 days/person compared with 1.4 days/person in the unvac-
inated group (p = 0.02) [13].
Only one trial reported the adverse effects of vaccination
14]. These were sore arm (51% vaccine versus 7% placebo)
nd erythema (11% versus 0%). This agrees with the sys-
ematic review where soreness was twice as common in the
accine groups compared with the placebo groups (RR = 2.1,
5% CI 1.4, 3.4) [28].
.4. Can inﬂuenza vaccine uptake rates be improved in
CWs?
Seven studies (with control arms) evaluated whether
romotional campaigns could improve uptake of influenza
accine in HCWs: two cluster RCTs [10,15]; one non-
andomised controlled trial [16]; and four before/after studies
17–20] (Table 5). The quality of the studies was limited,
artly because of biases and problems of confounding inher-
nt in the study designs, and partly because of poor reporting
r execution (Table 4). Direct comparisons are difficult as
tudy design and vaccination programmes were very differ-









Characteristics of accepted studies
Study Location Study design Setting Assessment Outcome measures
Randomised controlled trials
Carman [10] Scotland, UK Cluster RCT NHS long-term care geriatric
hospital wards
Protection of patients by the vaccination of
HCW against influenza
Patient mortality; virological monitoring;
vaccination uptake
Potter [11] Scotland, UK Cluster RCT NHS long-term care geriatric
hospital wards
Protection of patients by the vaccination of
HCW against influenza
Patient mortality; ILI infection; LRTI infection;
vaccination uptake




Saxen [13] Finland RCT Two paediatric hospitals Effectiveness of vaccinating HCW against
influenza
Respiratory infection; absenteeism
Weingarten [14] US RCT One hospital Effectiveness of vaccinating HCW against
influenza
Clinical influenza; absenteeism; side effects
Dey [15] UK Cluster RCT Primary healthcare teams and
nursing homes




Tannenbaum [16] Canada Before/after study
with control arm
Two nursing homes Effectiveness of campaign to vaccinate HCW
against influenza
HCW uptake rates
Cooper [17] Australia Before/after study 347-bed hospital Effectiveness of campaign to vaccinate HCW
against influenza
HCW uptake rates
Harbarth [18] Switzerland Before/after study 1500 bed hospital for primary
and tertiary care
Effectiveness of campaign to vaccinate HCW
against influenza
HCW uptake rates; reasons for non-uptake
Thomas [19] US Before/after study 300-bed nursing home Effectiveness of campaign to vaccinate HCW
against influenza
HCW uptake rates; reasons for non-uptake
Heimburger [20] US Before/after study Chronic care psychiatric
facility
Effectiveness of campaign to vaccinate HCW
against influenza
HCW uptake rates; Reasons for non-uptake
Christian [21] US Survey Acute care hospital Questionnaire of vaccination rates and reasons HCW uptake rates; reasons for non-uptake
Ganguly [22] US Survey Veterans hospital Questionnaire of vaccination rates and reasons HCW uptake rates; reasons for non-uptake
Nafziger [23] US Survey Two hospitals Questionnaire of vaccination rates and reasons HCW uptake rates; reasons for non-uptake
Nichol [24] US Survey 400-bed hospital Questionnaire of vaccination rates and reasons HCW uptake rates; reasons for non-uptake
Stephenson [25] UK Survey Three acute hospitals Questionnaire of vaccination rates and reasons HCW uptake rates; reasons for non-uptake
Watanakunakorn [26] US Survey 650-bed community teaching
hospital
Questionnaire of vaccination rates and reasons HCW uptake rates; reasons for non-uptake
DeAngelis [27] US Survey Paediatric medical healthcare
provides
Questionnaire of vaccination rates and reasons Reasons for non-uptake
RCT = randomised controlled trial; ILI = influenza like illness; LRTI = lower respiratory tract infection; HCW = healthcare worker.
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Table 2
Characteristics of trials evaluating the effect of vaccinating healthcare workers on patient morbidity and mortality
Potter [11] Carman [10]
Trial dates 1994–1995 1996–1997
Number of clusters 12 20
Setting NHS medical long-term-care geriatric hospitals in Scotland NHS medical long-term-care geriatric hospitals in Scotland
Intervention Vaccination routinely offered Vaccination routinely offered by letter and interview by trained
study nurses
Control Vaccination not routinely offered Vaccination not routinely offered
Vaccine match Reasonable match Good match to circulating strain
Influenza epidemic Yes Yes
Number of HCW 1078 identified in intervention group and 653 (61%) agreed
to participate and receive vaccination
1217 offered vaccination but number in control group not given
Health care workers involved Nurses, doctors, therapists, porters and ancillary staff Nurses, doctors, therapists, porters and ancillary staff
Number of patients 1059 (490 intervention, 569 control) 1437 (749 intervention, 569 control)
Randomisation procedure Hospital sites stratified by unit policy for vaccination and
then randomised to receive intervention or control
Random allocation, clusters balanced and stratified for policy of
vaccination of patients and size. Cluster paired by these
characteristics and one chosen from each pair by random
number tables for intervention
Outcomes 1. Patient mortality 1. Patient mortality
2. Influenza-like infection rates—patients
3. Lower respiratory tract infection—patients
2. Prospective virological monitoring (nose and throat swabs)
during winter epidemic on random sample (50%) of patients
3. HCW uptake rate4. HCW uptake rate
Mortality results Reduction from 17% (control) to 10% (intervention),
p = 0.013 (OR 0.56)
Uncorrected mortality reduction from: 154/688 (22.4%) control
to 102/749 (13.6%)intervention, OR 0.58 (95% CI 0.4–0.84),
p = 0.014.
All corrected rates significant except when corrected for
Barthel score, age, sex and vaccination profile together: OR
0.61 (0.36–1.04) (borderline p = 0.092)
HCW vaccine uptake rate Control = not given Control = 5%
Intervention arm = 61% Intervention = 50%
and increased by 5%–45% following the campaigns. The
most successful campaign was a mobile clinic in Australia
[17]. From a baseline of 8% this achieved a post-campaign
vaccination rate of 81% in staff in contact with patients and
49% overall. A similar mobile vaccination cart in the USA
achieved 61% uptake in a survey [24], and a subset of a further
study also supports this [18].
3.5. How cost-effective is the vaccination of healthcare
workers?
No studies were found which included the benefits to
patients from vaccinating HCWs. Three studies evaluated
the cost-benefit of vaccinating HCWs [29,30] or care work-
ers [31]; 11 studies evaluated other healthy adults [32–42].
They had either a societal or employers perspective, although
widely different designs, costs and parameters were used. Ten
out of these 14 studies (including both on HCWs [29,30])
were found to be cost saving.
In our base case analysis, (Table 5) which included the
costs of replacing staff arising from staff absenteeism, a vac-
cination programme was found to be cost saving, saving
approximately £28,000 for 1437 vaccinations (Table 6). This
equates to a saving of approximately £1400 for a 72-bed ward
or £12 per vaccinee. The base case assumes that NHS staff
w
pen in practice, an alternative base case excluding the cost
of replacing staff was tested. This cost £51/life-year gained
as no costs due to absenteeism were saved. Univariate sensi-
tivity analyses for each parameter were undertaken and in a
“worst-case” scenario (using the estimates for each parameter
that produce a less favourable estimate of cost-effectiveness)
the cost was still only £405/life-year gained (Table 6).
4. Discussion
4.1. Key results
The evidence for the indirect protection of patients at
high-risk for influenza and factors influencing vaccine uptake
by HCWs have not previously been the subject of system-
atic reviews. Our review suggests that vaccination of HCWs
against influenza protects HCWs and provides indirect pro-
tection to the high-risk. It is cost-effective and indeed prob-
ably cost saving.
4.2. Limitations and strengths
Only two trials examined the impact of immunising HCWs
against influenza on high-risk patients [10,11]. Sparse infor-









Characteristics and summary of the benefits of influenza vaccination in HCWs
Study Brief description Vaccine
match/epidemic
















1.1% vaccine vs. 8.9%
control (p = 0.001)
88% (47%, 97%) for
Influenza A (H3N2)
Mean absence (all illness)
days ± S.D.
Serum sickness, cellulitis and
lymphangitis in three controls
89% (14%, 99%) for
Influenza B
0.1 days ± 0.35 (vaccinated)
vs. 0.21 days ± 0.75 (control)
Not statistically different (no
p-value given)
Other than mild pain or
swelling at injection site, the
rest of the subjects reported
no significant adverse effectsGood quality trial Epidemic each year Influenza B: 0.6% vaccine vs.
5% control (p = 0.02)
Year 2: 0% vaccine vs. 7.1%




Vaccine (n = 216) vs.
placebo (n = 211)
Good match 1.8 episodes respiratory
infection per person (vaccine)
vs. 2 episodes (placebo)
N/A Mean absence (days) due to
respiratory infection
1.0 day (vaccinated) vs. 1.4













Poor match No significant differences
between trial arms for rates of
clinical influenza (23%
vaccinated vs. 22% control),
duration of flu or fever and
severity of flu. (p = 0.95)
N/A Mean absence (all illness)
(hours) (±S.D.)
Sore arm
51% vaccinated vs. 7%
control p < 0.05
Erythema, 11% vaccinated
vs. 0% control p < 0.05






Epidemic present 7.6 h ± 12.1 (vaccinated) vs.
8.2 h ± 18.3 (control).
(p = 0.91)
Percent employees absent
42.9% (vaccine) vs. 43.2%
(control) (p = 0.97)









Effectiveness of promotional campaigns on vaccine uptake in seven studies with control phase/arm
Study Setting and study
population
Study design Study details (n) Details of vaccine campaign Uptake rates Quality issues
Randomised/external comparison




Cluster RCT Large cluster trial; 64 PHCT;
34 NH; (n = 2984 HCW)
Letter ± public health nurse
visit and promotion;
Vaccination given by GP
PHCT 21.9% intervention,
21.0% control (p = 0.91)
Good quality although
randomisation procedures not
given in fullNH 10.2% intervention, 5.6%
control (p = 0.34)
Carman [10] UK; long-term
geriatric hospitals; all
HCW; data for nurses
only
Cluster RCT Vaccination programme vs.
no programme 10 clusters
each (approximately n = 2335
HCW)
Letters and interviews and
local vaccination
50% vs. 5% in control; 45%
increase
Overall good quality trial
although uptake was not main













16% before 26% after in
intervention




changes over time. Adjusted for
baseline characteristics.
However, only two sites and not
randomised. Note only 37% of
the intervention group attended
the sessions
Before/after study—internal comparator
Cooper [17] Australia; 347-bed
hospital; all staff
Before/after study (n = 880) Mobile clinic ‘needles on
wheels’
8% before 49% after
intervention (41% increase)
in all staff (81% after




control arm was from 4 years
previously and baseline rates not
given in staff with patient contact.
No statistics carried out. Cannot
assess the effects of potential
confounders changing over time




Before/after study (n = 5514) Main hospital: Adverts,
newsletter, personal letters;
vaccination in clinic
Main hospital: 23% (vs. 9%
in previous year) 14%
increase, p < 0.0001
Large, good quality study but
cannot assess the effects of
potential confounders changing





changed from 13% to 37%,
24% increase, p < 0.0001
Thomas [19] USA; 300-bed
nursing home; all staff
Before/after study (n = 195) Educational intervention and
staff vaccination fair with
vaccine offered
8%–46% (to 54% following
year)
Reasonable quality but no
statistical analysis and cannot
assess the effects of potential
confounders changing over time.
46% increase over 2 years






Before/after study (n = 1293) In-service meetings, video
tapes and pamphlets
16% before extended




PHCT = primary health care teams; NH = nursing homes; HCW = healthcare workers.
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Table 5
Base case parameters, resources and costs
Parameter Resource Unit cost Calculation
Patients and staff
Number of patients 1437 [10]
Number of staff and costs 2335 [10]
Doctors (n) 117 (5%) £24 ph (SHO) [43]
Qualified nurses (n) 747 (32%) [44,45] £17 ph (Staff nurse) [43]
Auxiliaries (n) 1191 (51%) [44,45] £12 ph (healthcare assistant) [43]
Others (n) 304 (13%) £12 ph (healthcare assistant) [43]
Costs of vaccination
Vaccine promotion campaign (admin,
stationery, postage)
2335 staff £0.70 per staff member Campaign arm = £1634; control
arm = £0
Vaccine cost
With campaign Uptake 51% [10] × 2335
staff = 1191
£6.59 per recipient [46] Campaign arm = £7847
Without campaign 5%[10] × 2335 staff = 117 £6.59 per recipient [46] Control arm = £769
Vaccine delivery recipient 30 min (include recovery time)
per recipient
Staff proportions and costs as above Campaign arm = £8454; control
arm = £829
Vaccine delivery staff (nurse) 5 min per recipient Nurse costs as above Campaign arm = £1687; control
arm = £165
Absenteeism (h per person) 7 h per vaccinated staff; 10 h per
non-vaccinated staff [12,28]
Staff proportions and costs as above Campaign arm = £280826;
control arm = £326580
Total costs (for 1437 patients) Campaign = £300449;
control = £328344
Net cost (campaign − control
costs) = −£27895 = cost saving
Effects
Mortality in patients (campaign, control) 13.6%, 22.4% [10]
Discount rates 3.5% [47]
Percent males 30% [10]
SMR (nursing homes) 600% [48]a
Age distribution (m)(f), general
population [49]b
M/F Discounted life expectancy taking SMR
into account (m)(f) (years) [50,51]
Overall life expectancy = 2.75
years
Under 60 3%/1% 9.10/10.96 Mortality reduction:
(campaign − control)
22.4% − 13.6% = 8.8%
Life-years gained: (for 1437





SHO = Senior House Officer.
a To express the value of immediate deaths prevented in life-years gained, it is necessary to estimate the life expectancy of nursing home patients. The
standardised mortality rate (SMR) of 600% was applied (as an odds ratio to the annual risk of death) to general population life tables [20,21]. This led to a
discounted life expectancy for any age and sex. These were then weighted by the population balance shown in the above table to give the overall life expectancy
of 2.75 years.
b Rounding errors in males.
Table 6
Alternative scenarios derived from sensitivity analyses
Parameter Base case No absenteeism Pessimistic scenario
Cost of promotion per recipient (£) 0.70 0.70 2
Cost of vaccine per recipient (£) 6.59 6.59 10
Absenteeism reduced per person (h) 3 N/A 0
Life expectancy (years) 2.75 2.75 1.5
Mortality reduction (%) 8.8 8.8 4
Nurse time to vaccinate (min) 5 5 10
Staff uptake rate (%) 51 51 70
Discounting (%) 3.5 3.5 3.5
Additional cost Saving of £28000 £18000 £35000
Life-years gained 350 350 86
Result Cost saving (approximately £12/vaccinee) £51/life-year gained £405/life-year gained
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Both trials were conducted in long-term geriatric hospitals in
the UK and these have tended to be replaced more recently
by smaller nursing and residential homes, raising questions
about the generalisability of the findings. An ongoing cluster-
randomised controlled trial in 48 nursing homes in England
(Andrew Hayward, personal communication) should provide
further and more appropriate information for the UK. The
advantage of our model is that the spreadsheet (available
from authors) is simple and transparent, and can be adapted
to model different scenarios as more data becomes available
or to reflect practice or costs in other countries. Ideally, a
more sophisticated model would reflect influenza transmis-
sion, however, there is currently insufficient information to
support such an approach.
Although only a limited number of studies were identified
answering the question of effectiveness, the main findings
were generally consistent, despite differences in design, set-
ting and influenza-related morbidity outcomes.
4.3. Policy implications for the future
There is very low uptake of vaccination in HCWs despite
this being the official policy in most European and North
American countries. In Europe in 2000 only five of the 26
countries responding to a questionnaire survey of influenza





























New strategies to improve influenza vaccination uptake
are required—there is potential for considerable health gain
and possible savings to be made.
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